Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECIPROCAL: Adaptive vs Standard Dosing of 177Lu PSMA RLT in mCRPC
NCT07200830Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2026
- Primary completion
- Sep 2034
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cancer and Leukemia Group B. Started Mar 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07200830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200830.